Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dutasteride Pharmacodynamics in BPH and Prostate Cancer
NCT00375765Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2005
- Primary completion
- Jul 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dutasteride in benign prostatic hyperplasia (BPH) and prostate cancer (PCa) (2 arms), sponsored by GSK. Primary endpoint: Relative change in PSA expression per cell at 3 months. Started Apr 2005; status: completed.
02
Drugs
dutasteride
03
Conditions
benign prostatic hyperplasia (BPH)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00375765.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00375765.